BaFin flags Pentixapharm 2024 financial statements, cites EUR 34.7 million intangible asset overstatement
PUBT · 1d ago
Share
Listen to the news
- Bafin concluded its review of Pentixapharm’s FY2024 consolidated financial statements with an error finding.
- Regulator views intangible assets as overstated by EUR 34.7 million.
- Capital reserve seen overstated by EUR 21.6 million.
- Overstatement includes EUR 21.6 million from purchase price allocation amounts at a former shareholder level.
- Another EUR 13.1 million relates to PentixaFor development costs from 2021-2024 that Bafin says failed capitalization criteria.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2409820_en) on October 02, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending